TRAIL receptor signalling and modulation: Are we on the right TRAIL?

This publication has 116 references indexed in Scilit:

• Targeting TRAIL death receptors
  Current Opinion in Pharmacology, 2008
• Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
  Nature Medicine, 2007
• Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein
  Molecular Cancer Therapeutics, 2007
• The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
  Apoptosis, 2006
• Proteasome inhibitor MG132 sensitizes HPV‐positive human cervical cancer cells to rhTRAIL‐induced apoptosis
  International Journal of Cancer, 2005
• Cancer genes and the pathways they control
  Nature Medicine, 2004
• Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms
  The Prostate, 2004
• Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells
  Oncogene, 2003
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily
  Nature Reviews Cancer, 2002
• Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
  Cell Death & Differentiation, 2000